WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has recently received approval from the European Medicines Agency (EMA) for its Dundalk, Ireland facility to engage in commercial manufacturing of an innovative biologic for a global client. This milestone approval further solidifies WuXi Biologics’ standing, with multiple facilities having obtained EMA and FDA nods for commercial production of the same product since 2023. Dr. Chris Chen, the CEO of WuXi Biologics, highlighted the significance of this EMA approval, emphasizing the company’s commitment to meeting client demands and underscoring the efficacy of its Global Dual Sourcing Strategy in providing adaptable and robust manufacturing solutions across various regions while upholding a consistent record of regulatory endorsements. The company’s focus remains on supplying high-quality, life-saving treatments to a global clientele, ultimately benefiting patients worldwide.
WuXi Biologics’ Global Dual Sourcing Strategy is structured around utilizing numerous qualified manufacturing sites globally for a given product line, thereby improving patient access at a regional level. With the recent EMA approval, WuXi Biologics now boasts multiple endorsed sites spanning different regions for this groundbreaking biologic, showcasing the company’s competence in delivering regulatory-compliant manufacturing services from any site within its extensive global network. Additionally, the EMA authorization signifies the maiden commercial debut of a biologic from WuXi Biologics’ Ireland facility, post its complete Good Manufacturing Practice (GMP) authorization from the Irish Health Products Regulatory Authority (HPRA) in 2024. This facility, recognized with the prestigious ISPE Facility of the Year Award (FOYA) in 2023, is equipped with state-of-the-art 6,000L perfusion and 48,000L fed-batch capacities, solidifying its role as a pivotal manufacturing center within WuXi Biologics’ worldwide network. Notably, the facility achieved a flawless 100% success rate across various extensive Process Performance Qualification (PPQ) runs, including a remarkable 16,000-liter scale operation achieved by amalgamating four 4,000-liter single-use bioreactors—representing one of the most extensive cell culture processes utilizing single-use technology on a global scale.
Having surpassed 42 regulatory inspections with flying colors—comprising 22 by the EMA and FDA respectively—and securing 97 license approvals from global regulatory bodies by the conclusion of 2024, WuXi Biologics maintains an impeccable 100% success rate in global regulatory assessments, devoid of any critical findings or data integrity discrepancies. This unified quality management system facilitates seamless technology transfers, ensures site equivalency, and guarantees compliance with the most stringent international standards. WuXi Biologics stands out as a premier global CRDMO offering comprehensive solutions that enable partners to explore, develop, and manufacture biologics from inception to commercialization, all aimed at advancing patient care on a global scale.
Key Takeaways:
– WuXi Biologics’ Ireland facility secured EMA approval for commercial manufacturing of an innovative biologic, adding to its array of approved sites globally.
– The company’s Global Dual Sourcing Strategy enhances regional patient access by deploying multiple qualified manufacturing sites for a single product family.
– WuXi Biologics’ Ireland site, equipped with cutting-edge capacities, achieved a 100% success rate in extensive Process Performance Qualification (PPQ) runs, solidifying its pivotal role in the company’s global manufacturing network.
– With a flawless track record of regulatory inspections and license approvals worldwide, WuXi Biologics upholds the highest standards of quality and compliance in the biologics manufacturing industry.
Tags: regulatory, data integrity, cell culture
Read more on pharmabiz.com